DocGo Inc. (DCGO) Earnings Call Transcript & Summary

March 13, 2023

NASDAQ US Health Care Health Care Providers and Services earnings 41 min

Earnings Call Speaker Segments

Mike Cole

executive
#1

Thanks, operator. Now, before I hand things over to management, I'd like to offer a few comments about forward-looking statements. Anything said on this conference call that isn't a historical fact counts as a forward-looking statement. Terms such as anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, along with similar wording, typically serve to flag these forward-looking statements; such statements don't guarantee future performance and could involve and are subject to particular risks, uncertainties, and other factors that might impact DocGo's business, financial condition, and other operating results. Among these are the risk factors and other qualifications laid out in DocGo's annual report on Form 10-K, quarterly reports filed on Form 10-Q, plus other reports and statements DocGo files with the SEC, to which your attention is directed, though this list isn't exhaustive. What actually happens and the results achieved could differ materially from what these forward-looking statements express or imply. Also, references to non-GAAP financial measures appear on today's call. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures are supplied directly as part of this call or are included in the earnings release, which appears on our Web site, DocGo.com, and in our filings with the Securities and Exchange Commission. What's contained in this call is accurate only as of the date discussed. Investors shouldn't assume statements will stay relevant and operative at a later time. We're under no obligation to update any information discussed in this call in the future. At this point, it's my pleasure to turn the call over to Mr. Anthony Capone, CEO of DocGo. Anthony, please go ahead.

Anthony Capone

executive
#2

Thanks, Mike. When we look back at 2022, we did a remarkable job of methodically swapping out large revenue streams from mass COVID testing and bringing in a range of new programs, all while building the groundwork for ongoing profitable expansion in 2023 and afterward. During 2022, our revenues came to 440.5 million, compared with 318.7 million in 2021, which represents 38% growth. If you set aside revenues from mass COVID testing, we achieved 75% growth year-over-year. When last year began, our initial revenue guidance called for 400 million to 420 million, along with 35 million to 40 million in adjusted EBITDA, and we take pride in having met both of those measures. Together with our 2022 results today, we are rolling out 2023 guidance of 500 million to 510 million in revenue and 45 million to 50 million in adjusted EBITDA. For the year, our gross margin expectations are 35%. In Q1 and Q2, gross margin should come in a bit under that level, then improve by roughly 50 to 75 basis points each quarter as the year goes on; we expect to end 2023 with gross margin at an annual rate of about 37% and an adjusted EBITDA margin of about 13%. Over the longer term, our target consolidated gross margin is still 40%; today we are sharing our backlog for the first time, which we define as projects that have been awarded but have not yet begun or been fully implemented. Our backlog currently stands at $180 million across three years. We expect this backlog to be completely rolled out by the close of the third quarter of this year. This backlog provides us with outstanding visibility into 2023 revenue and lets us offer 2023 revenue guidance with a great deal of confidence. At this point, I'll turn things over to Lee Bienstock, our President and Chief Operating Officer, to give an update on some of our key growth initiatives.

Lee Bienstock

executive
#3

Thank you, Anthony. We felt a great deal of satisfaction when we shared news not long ago about several contracts we had won, and we keep chasing sizable openings that are making their way through the request-for-proposal pipeline. Among the items in that recent release was a medical transportation agreement worth $94 million with a large hospital system — the biggest RFP award we have landed so far. Under this arrangement, every hour is leased at 100%, which gives DocGo protection on the downside margin along with considerable upside. Looking ahead through 2023, we anticipate additional momentum for our population health solutions in fresh markets, including Connecticut and Chicago. Not long ago we captured an RFP to deliver occupational health services to public health employees in Southern California, and we have reached the closing phases of a public health RFP covering remote patient monitoring plus chronic care management in Illinois. At present, DocGo has 34 live RFP submissions awaiting a decision, representing more than $1 billion in total contract value. An award to DocGo cannot be guaranteed, so none of these RFPs appear in our present guidance. On the foundation of a distinctive clinical delivery approach that draws on medical professionals who cost less, we have assembled one of the country's biggest mobile health workforces. Because the pool of these clinicians is so large, we can expand rapidly and still achieve unit economics that are highly profitable. What's more, our reimbursement model based on leased hours delivers downside margin protection, which reduces the demand risk we face. The attractiveness of the value proposition we offer customers is underscored by our recent wins in the RFP channel and by rising interest in DocGo services nationwide. It's worth noting that our pilot with Dollar General keeps moving forward too; patient volume has risen week over week, and the week just past brought the strongest demand we have ever recorded; an exceptionally strong customer Net Promoter Score gives further evidence of this program's appeal; in a survey conducted recently, almost every patient who has tried the service says they would tell a friend to use it and intend to use it once more. Pilots are something DocGo has and will keep having, and those are reimbursed through fee-for-service. Even so, we have no intention of growing any pilot on a fee-for-service basis in cases where demand risk falls on us. Before any pilot project, our current payer pilots included, can be expanded, a reimbursement model must be in place that guarantees downside margin protection for the company. At this point I'll turn things back over to Anthony.

Anthony Capone

executive
#4

Thank you, Lee. We're very enthusiastic about the expansion opportunities ahead in 2023, but at the same time we're sharply focused on getting the most out of profitability and trimming expenses wherever it makes sense. One strong illustration of that work is the rapid normalization effort we kicked off at the start of February. As we've said many times before, the initial 90 to 120 days following the debut of a new program carry heavier costs than the mature programs that have already been operating for more than 6 months. Usually, the biggest cause of that extra expense is what we spend on staffing agency labor in order to get programs up to speed fast. That capability gives DocGo a clear edge over competitors, yet it turns into a near-term cost. Usually, when we bring in clinicians from a staffing agency, the rate we pay runs roughly 40% above what a traditional W2 employee would cost. Once 90 days have passed, we're able to bring that clinician on board with no extra charge from the agency. Our aim is to bring that down to 60 days at some point during 2023, which should not only lift profitability but also let us potentially expand more quickly, since we'd be better positioned to absorb the upfront expenses tied to the fast growth we're seeing; that effort, together with other initiatives — like cutting back on rented vehicles as we secure long-term vehicle leases, and our push to lower overtime during project launches — should also have a favorable effect on margins as the year goes on. Taken together in 2022, we calculated that all of these elements weighed on margins by roughly 600 basis points. Luckily, every one of these costs stems from our considerable growth. We'll keep working to lessen these costs as time goes on. We also anticipate generating stronger profitability from our medical transportation business in 2023. More specifically, we're continuing the work of shifting the medical transportation business we already have onto a leased hour model before the year is out. Half of that existing medical transportation business is fee-for-service, an older model that's exposed to demand fluctuations. Our leased hour model, which is gaining in popularity, delivers far better visibility into revenues and margins. Because demand from health care institutions for this service is so remarkably strong, it gives us a fantastic chance to get a foot in the door and grow that relationship into mobile health care offerings like our RPM and our ER readmission avoidance programs. Over the course of 2023, we'll be repositioning medical transportation assets so they serve these more profitable leased hour contracts, while we stop providing service in certain markets where profitability is weaker. We've already started pulling out of markets that aren't hitting our target margins. We anticipate that these changes as a whole will have a significant favorable effect on medical transportation margins throughout the year, with only a minimal effect on revenue. On top of that, it's worth pointing out that May 11 of this year is when the Federal public health emergency is scheduled to end. We've been getting ready for that, and it's completely factored into our 2023 revenue and EBITDA guidance. Right now, I'll pass things along to Norm Rosenberg, our CFO, so he can walk through the financials.

Norman Rosenberg

executive
#5

Thanks, Anthony, and good afternoon to everyone. I'll start off my remarks with a review of the full year results, and after that I'll move on to talk about the fourth quarter. For the 12 months that ended December 31, 2022, total revenue came in at 440.5 million, which works out to growth of 38% compared with total revenue of 318.7 million for the year that ended December 31, 2021. Mass COVID testing revenues during 2022 were estimated at roughly 75 million, versus 110 million in 2021. If you take those revenues out of both periods, revenues rose by 75%. The year-over-year revenue growth came from a mix of expanded relationships with existing customers, the addition of new customers, and inorganic growth through acquiring licenses and capabilities in various markets. Mobile health revenue reached 325.8 million in 2022, an increase of 39% from 234.4 million in 2021. Again, if you strip mass COVID testing revenues out of both periods, mobile health revenues doubled in 2022. Our mass COVID testing contracts wrapped up in September of last year, but we do still hold standby surge contracts, and those will once in a while bring in fairly minor amounts of revenue, as we saw in Q4. Medical transportation revenue came to 114.7 million in 2022, up 36% from 2021. Both organic and inorganic sources drove that growth, through higher trip counts, a higher average price per trip, or what we refer to as APC, and continued adoption of our leased hour model, under which we provide an ambulance along with related personnel and equipment for a fixed daily or hourly fee. Gross margins came in at 35.1% in 2022, an improvement from 34.4% in 2021. Mobile health gross margins were 38.9% versus 38.1%, while transportation gross margins stood at 24.5%, essentially the same as the 24.7% posted in 2021. Adjusted EBITDA for 2022 was 41.3 million, an increase of more than 60% over the adjusted EBITDA of 25.1 million for 2021. Net income for 2022 came to 30.7 million, up almost 60% from 19.2 million in 2021. EPS was $0.34 on both a basic and fully diluted basis in 2022, an increase from $0.30 on a basic basis and $0.25 on a fully diluted basis in 2021. Now let me turn to the fourth quarter. Total revenue for the fourth quarter of 2022 was 108.8 million, versus 121.3 million in the fourth quarter of 2021, which had included an estimated 49 million in mass COVID testing revenues. By contrast, mass COVID testing revenues made up a relatively insignificant portion of total revenues in the fourth quarter of 2022. If you remove those testing revenues from both periods, recurring underlying revenues grew by roughly 49% year-over-year in the fourth quarter. Mobile health revenue for the fourth quarter of 2022 was 71.8 million, compared with 102.6 million in the fourth quarter of 2021. Again, if you look at recurring mobile health revenues by taking mass COVID testing revenues out of both periods, mobile health revenues grew by 32%. Medical transportation revenue rose significantly to 37 million in Q4 of 2022, nearly doubling from the levels we saw in the fourth quarter of 2021. During Q4, we saw year-over-year expansion in just about all of our main transportation markets, and we closed out the year carrying substantial momentum. Our net income came in at roughly 7.1 million for the fourth quarter, versus net income of 20.3 million during Q4 of 2021. A number of sizable non-recurring items landed in the other income and expense lines and affected net income for the fourth quarter of 2022. For additional detail on those items, please see the financial statements that accompany the earnings release. Net income in last year's Q4, naturally, reflected a $5.2 million gain tied to remeasuring warrant liabilities. Those warrants, as you'll remember, were redeemed during Q3 of last year. Adjusted EBITDA reached 6.8 million in the fourth quarter of 2022, compared with 17.3 million of adjusted EBITDA in the prior-year fourth quarter. Total gross margin percentage for Q4 of 2022 came to 39%, versus 40.7% during the same stretch of 2021; gross margins in both periods, mind you, got a lift from items above their typical run rate levels. The fourth quarter of 2021 got a boost from a spike in COVID testing revenue. In Q4 of 2022, we booked meaningful savings across several insurance expense categories, along with a decrease in certain revenue reserves stemming from cash collections, which pushed margins upward. Gross margins for the mobile health segment during the fourth quarter of 2022 were 43.9%, against 44.7% for Q4 of 2021; meanwhile, in the transportation segment, gross margins climbed to 29.4% in Q4 of '22, rising from 20.7% in Q4 of 2021. We recently decided to exit the transportation business in California, which by our estimate was costing us roughly $1 million in EBITDA each year. The mobile health business will keep operating across all of California. As a company, we've reached a stage where a significant set of opportunities lies before us to pursue, and our intent is to concentrate on those markets and business lines offering the highest expected returns on investment. Now to the balance sheet. At December 31, 2022, total cash and cash equivalents, including restricted cash, stood at 164.1 million, compared with 179.1 million at the close of fiscal '21 and 179.4 million at the close of Q3. Several factors drove the cash reduction during the fourth quarter, among them the timing of payments from high quality credit customers, which produced an increase of approximately $8 million in accounts receivable, $3 million in acquisition payments and capital expenditures, and roughly $3.2 million spent on stock buybacks. Those factors more than offset the cash generated by our regular operations. Operating cash flow for the full year was about $29 million. Acquisitions and capital expenditures consumed $41 million, and share repurchases during the year totaled $3.7 million. In Q4, we repurchased roughly 465,000 shares, paying on average $7 apiece; our intention is to keep leveraging the balance sheet in support of the stock buyback initiative that's already underway, under which about $36 million remains available. Along with a $90 million credit facility that might be upsized by as much as another $50 million, we possess the financial capacity to carry out buybacks and acquisitions as well as put money into new business lines and projects, all without needing to bring in fresh capital; our emphasis remains on the capital-light approach, while we also pursue chosen acquisitions financed through cash generated by operations. Given that the cost of capital is climbing in the marketplace, this hands us a clear edge over competitors; shifting now to what we expect in 2023. We foresee demand staying robust among our customers across both mobile health and transportation services. Per what Anthony said, our full-year revenue guidance falls between $500 million and $510 million. Although that bracket implies top line growth versus last year of roughly 14% to 16% once you strip out the 75 million in mass COVID testing from the 2022 revenue baseline, and given that we anticipate zero mass COVID testing revenues during 2023, what we're actually seeing is top line growth of around 36% to 40%. We expect growth during 2023 to come mainly through organic channels and same-store sales. Adjusted EBITDA should land somewhere between $45 million and $50 million; we anticipate closing out 2023 with a gross margin annual run rate near 37%, which ought to be our strongest quarter of the year, plus an adjusted EBITDA margin of roughly 13%. That wraps up my financial remarks. At this point, I'd like to return the call to the operator so we can begin the Q&A session.

Richard Close

analyst
#6

All right, thanks. Am I coming through clearly?

Anthony Capone

executive
#7

Yes, Richard, we've got you. Good to have you back on the line.

Richard Close

analyst
#8

Great. Nice work on the year and the guidance. Anthony, could you discuss the startup, the ramp-up costs, and perhaps the categories, what makes up those costs — for instance, what portion is tied to labor versus other expenses when it comes to securing business and launching those contracts? And then regarding the 108 million in revenue that was one — I believe from January, the start of January, what amount of the startup costs do you figure relates to those contracts?

Anthony Capone

executive
#9

Those are good questions. The makeup was definitely skewed much more toward labor, both labor for staffing agencies and labor for overtime. When we examined 2022 during just that period, subcontractor costs came to roughly 12 million and overtime came to roughly 14 million, while the other big category, or meaningful category, was vehicle rentals, at roughly 3 million; those are the three primary categories and all of them are in excess; so it matters to grasp that this isn't the total we spent on subcontractors or overtime, it is measured against what we consider to be in excess; so in reality the sum we spent is significantly greater than that. But measured against what we call a normal mature run rate basis, moving forward from there, there was excess cost; so those are the three largest ones; overtime, subcontractor and then vehicle rental.

Richard Close

analyst
#10

Okay.

Anthony Capone

executive
#11

So moving forward with the 100 — sorry, please continue. Regarding the 180 million going forward, for the time being you'll still see comparable percentages on those, or they have comparable ramps. And just to remind everyone, we had disclosed that we intend to have the 180 million fully ramped by the end of Q3. The one big difference is that we've already started our rapid normalization project; so that will also be sort of reaching completion in Q3; so I would anticipate that the upfront costs on that 180 million will be lower than what they've been historically.

Richard Close

analyst
#12

All right. And to build on what we discussed regarding the swift normalization, will that end up completely implemented, with all those advantages showing up in these contracts, or does it improve step by step as we go along?

Anthony Capone

executive
#13

I would describe it as step by step, starting when we kicked things off last month and continuing through Q3. So roughly half the projects, you could figure, are receiving the fullest advantage, and a number of them are already being deployed to the 180 million at this point. Still, I would characterize it as pretty linear, with gains occurring from February through Q3 when it comes to lowering those roughly 600 basis points that are presently affecting us because of the excess costs.

Richard Close

analyst
#14

All right, excellent. Nice work. I'll get back in line. I'm certain plenty of other folks have a good amount to ask too.

Ryan MacDonald

analyst
#15

Hello there. I appreciate you fielding my questions, and congratulations on a strong quarter. Perhaps the opening question goes to Lee. When we consider the pipeline, you mentioned RFPs — I believe 34 or so — that are awaiting a decision. What should we expect regarding the timing for those decisions to come through? And regarding the typical size of those RFPs, what range are we talking about? Does it lean more toward 1 to 10 million, or was it, I think, grouped into 10 to 200 million? Thank you.

Lee Bienstock

executive
#16

Yes, certainly. So to begin with the timing, those truly do differ; on certain ones, we might hear back within a matter of weeks, while on others it might take, say, a couple of months. The timing really rests with the organization issuing the RFP as part of that process. So it genuinely differs, ranging from weeks to just a couple of months. As for the average size, we've boosted it considerably. Initially we began at the size you referenced, roughly the $10 million mark. However, we've raised that dramatically, so 30 million to 50 million is now our typical submission. So we're pursuing bigger opportunities, and we're pursuing a greater number of opportunities.

Ryan MacDonald

analyst
#17

That's really useful, thanks. Then Anthony, this one's probably for you. You mentioned the 180 million, of course, that's going to be phased in by the third quarter. How should we begin thinking about, I suppose, the revenue that flows into the model? Is this something that, as you said, spans three years — meaning it's recognized ratably, so roughly 60 million annualized each year beginning in the third quarter? What's the right way to frame that?

Anthony Capone

executive
#18

Yes, that's exactly how to view it; we need to ramp up to that level, so clearly it isn't 60 million right away; however, that 180 million sits within the current guidance for this year. And what that does for us, when we compare last year's figure against the guidance we just provided, is that the 60 million essentially lets us account for our whole guidance for this year rather than relying on a plug.

Ryan MacDonald

analyst
#19

That's useful. Maybe I'll squeeze in one final question about the leased hour model as you begin that shift, moving 50% and attempting to get every customer onto it. What are your expectations, I suppose, regarding keeping customers as you go through that change? And if there's any resistance you're encountering related to the switch, what does that look like?

Anthony Capone

executive
#20

Right now, demand for medical transportation is incredibly high. Because of that, changing providers is extremely, extremely difficult for a customer; it's quite uncommon for us to encounter a customer unwilling to make the change. There are exceptional situations in which someone might not, but that is definitely uncommon. From a percentage standpoint, I don't know which customers will make the change and which won't; however, what I can tell you is that we have been discussing this matter with our customers for more than a year; therefore, they are fully aware that upon contract renewal, the sole choice available is to renew under a leased hour program, meaning neither party will face any surprises, should they choose not to proceed. That said, for any hospital system, switching ambulance providers at this moment would be extremely, extremely difficult.

Ryan MacDonald

analyst
#21

Great, thanks for the additional detail.

David Grossman

analyst
#22

Good afternoon, and thank you. Anthony, I’d like to start by revisiting something you just addressed regarding the $180 million in backlog that’s converting into revenue. So is it fair to think that, once everything is fully in place, this represents roughly $60 million in ARR contribution, with a quarter of that showing up in ’23 and a full year of it in ’23? Is that the right way to frame it? Put another way, does essentially all of it land in revenue during the fourth quarter and then remain at that level for all of next year?

Anthony Capone

executive
#23

No. I believe it’s certain that on a full run rate basis you’re there for the entire fourth quarter. However, a lot of those contracts have already started rolling out as we speak. As of today, they are already in the process of rolling out. So I’d describe the progression from now through the end of the fourth quarter as fairly linear between now and then; but once you’re through the entire fourth quarter, you’re at that full revenue run rate which, annualized, isn’t precisely 60, though it’s close enough.

David Grossman

analyst
#24

Alright, so it goes up in a straight line to roughly 60 million, and after that you'd move to 50 million each quarter in '24, I think, is that right?

Anthony Capone

executive
#25

That's right, yes. After that, it keeps going for another three years, through '24 and '25.

David Grossman

analyst
#26

Understood, thank you. Now regarding profitability, is it fair to think that — from what I recall in your prepared comments, you mentioned roughly $1 million of EBITDA headwind tied to leaving the California transport business, plus a negligible effect on revenue. Did I get that correct, meaning the '23 guidance already accounts for that $1 million EBITDA headwind?

Anthony Capone

executive
#27

Yes, it's in there. That has already been incorporated into the guidance we provided.

David Grossman

analyst
#28

Understood. And the final item I had was regarding how we should approach startup costs. You've done a nice job explaining that you're sitting at these high levels and working to reduce them. By the time we finish this year, it sounds like you'd expect to have removed a significant portion of those costs from the ramp, thanks to some of the staffing moves you're making and also on the vehicles. How do you view it as you head into '24 and then ramp up? Do you believe the vast majority of that 600 basis points will be out of the system by the time this year ends?

Anthony Capone

executive
#29

No, I'd say roughly half of it. If you consider it, we're at approximately 120 days right now and we're aiming to reach 60 days, so essentially you're halving the duration of your startup. Yet there's definitely that 60 days of runway to expand. And we have further plans designed to remove that 60 — the 60-day window of startup expenses on the labor side. I won't dive into too much detail here, since I don't want to ruin all the good material for the next earnings call; but we have many plans for 2024 to capture the extra 60 days so that there's practically zero startup costs; and we'll kick off those initiatives once we complete this rapid normalization initiative. But the present rapid normalization initiative is about moving from 120 to 60, so you can view it as capturing those sorts of 300 basis points out of the 600.

David Grossman

analyst
#30

Understood. Then, for Norm, one final item: what figure ought we to apply regarding CapEx when it comes to 2023?

Norman Rosenberg

executive
#31

Well, normally — and we talk about a capital-light approach, naturally, in which we generally prefer leasing over purchasing — yet that calculation is no longer the same. David, as you're aware, correct, we're weighing our cost of capital against the expense of leasing, and rates keep climbing. I'd say for this year, I believe during 2022, we laid out roughly 3 million and some change for CapEx. My expectation would be a number fairly close to that.

David Grossman

analyst
#32

does that take in software that's been capitalized?

Norman Rosenberg

executive
#33

a small amount of capitalized software would be part of that.

David Grossman

analyst
#34

Excellent. OK, everyone, I appreciate it.

Richard Close

analyst
#35

I appreciate you taking my second question. Anthony, during your comments on Dollar General, you brought up something regarding fee-for-service, and you said that down the road you'd like to operate entirely under the leased rate model. Could you expand on that a bit, specifically how you see a relationship such as the one with Dollar General transitioning into the leased hour model too?

Anthony Capone

executive
#36

Yes, that's a wonderful question; there are two ways to go about it. The main thing is to adopt an approach similar to how the ambulance 911 system operates. DocGo doesn't have much of a presence in that 911 ambulance system at all. But the way it functions is that the county provides subsidies for the ambulances, since the county requires those services. If ambulances weren't available, the healthcare people receive would be significantly worse. And suppose you approach a county and point out that within their borders there are hardly any healthcare facilities — just a tiny bit of primary care, but nothing for urgent needs, or the reverse situation. Would you be open to leasing this to us at an extremely modest rate? Remember, all they're covering is the gap between our insurance reimbursements and the daily minimum, and that gap can occasionally be zero. Would you lease this model so health care stays available in your county? Combine that with the standing and esteem Dollar General holds locally, and by joining the two, you're essentially delivering something to the county—one where officials will agree, at fairly minimal expense, to ensure residents can reach top-tier care on both the primary and urgent sides. Then there's the other route, which involves going to the payers. You approach those payers, and they end up covering the leased hour model — we already have cases of that happening right now. It isn't with Dollar General, though we do have instances in other parts of our organization where payers cover costs based on leased hours. So as we keep growing these pilots, those are the two paths we're looking at.

Richard Close

analyst
#37

Regarding the counties, have those discussions happened yet, and are they going over well?

Anthony Capone

executive
#38

Yes, I've held a few in the local areas, and my sense is they're quite well understood. It also matters to grasp how tiny that dollar amount is. So one reason they're understood well, or received well, is that an ambulance contract often runs into many, many millions of dollars for a local municipality. That's because collection rates for these ambulance services tend to be very, very low, which explains why DocGo avoids 911. In this instance, though, collection rates are in fact very high. We already see that today in our capacity to fee-for-service. We simply don't want to take on demand risk. So the real sum the county must confront is extremely low. So the sell becomes far, far simpler for them to obtain very high quality service.

Richard Close

analyst
#39

All right. Thanks.

Kieran Ryan

analyst
#40

Hey, everyone. Kieran Ryan here, filling in for Pito. Appreciate you taking my question. To start, I'd like to nail down one thing upfront. From what I recall, the last time I looked, your transportation segment's KPIs didn't factor in leased hour contracts. Now that you're placing greater emphasis on those leased hour contracts — with one very large one arriving this year — I'm curious: will you change that? Will you adjust how those KPIs get reported, or make other changes, so we can track the progress there more effectively?

Anthony Capone

executive
#41

That's an intriguing idea. There's a great deal of logic behind it, I'd say. You'd need to step back and consider what it would involve. Would we measure leased hour by revenue, by trips, by shifts, or by hours? You could approach it in quite a few different ways. Still, it's definitely an interesting metric — one we track internally. So we'll talk it over and revisit it, but I believe it makes a great deal of sense.

Norman Rosenberg

executive
#42

Hey Kieran, Norm here. Let me jump in on that. My sense is that so long as fee-for-service stays a fairly meaningful portion of what we do, we'll likely keep reporting both our trip count and our APC. It's also really useful for us as a means of spelling out the reason transport margins have improved so strongly, on both a sequential and a year-over-year basis, since our APC sits higher — correct? That isn't luck; we're handling trips of greater acuity, more advanced life saving trips or critical care trips, and it has made an enormous difference; it's certainly among the factors pushing margin, and it was built into the plan. Something you'll pick up on: once you run the numbers, if you take overtime, if you take trip count times the average price per trip, and then set that against total transport revenue, you'll find that it accounts for — the fee-per-service portion accounts for a shrinking share of transport revenue overall, with what's left coming from the leased hour model.

Anthony Capone

executive
#43

One additional thing I want to mention, and this is something we've already communicated. All the fresh agreements we've entered into within the transportation business are structured as leased hour contracts. What that means is that from here on out, we aren't bringing in any fee-for-service agreements. Going forward, every single one of them will be a leased hour contract.

Kieran Ryan

analyst
#44

That's really useful, thanks. One fast additional question. You said the PHE roll off has been factored into your guidance. Could you provide a bit more detail on the mechanics, specifically how that affects the business? Thanks.

Anthony Capone

executive
#45

Here I'll reveal my lack of knowledge. PHE is — ?

Kieran Ryan

analyst
#46

My apologies — the public health emergency.

Anthony Capone

executive
#47

Thanks for assisting us in attempting to reach that point. Regarding the public health emergency, our preparations have spanned a considerable period. Consequently, there are numerous — it is quite — once it took effect, it had an effect on a great many matters. Thus there isn't a single magic solution for reducing its impact; however, the most significant element of that reduction is simply ensuring we avoid operating on a fee-for-service model; therefore, for the majority of businesses currently using fee-for-service, how insurance reimbursement functions, or how Medicare reimbursement functions, has a truly substantial effect on the amount reimbursed under whatever fee-for-service code applies. Once that ends, they could receive reduced payments from Medicare, receive reduced payments from managed care organizations, which occurs because we don't engage in fee-for-service work; that doesn't apply to us; it consisted of cuts to Medicare or adjustments to the Medicare fee schedule as between telehealth and in-person visits; hence our preparations have been underway for a considerable period, and we've structured contracts so that no impact falls on us. And once more, all of it is completely incorporated into the guidance we provided.

Kieran Ryan

analyst
#48

Thanks.

Anthony Capone

executive
#49

Thank you, operator. Before we wrap up today's call, I'd like to mention that an in-person Investor Day is scheduled for June 30 of this year at NASDAQ's market site in Times Square, running from 1.30 to 3 pm. At that gathering, we'll lay out in detail DocGo's vision for the future of healthcare. Tech demos, Q&A, and a chance to meet the whole DocGo executive team will all be part of the session. We're hoping plenty of you can make it. And finally, I want to express appreciation to our team. DocGo's value equation brings together our proprietary technology and the dedication of our hardworking 5,000 plus workforce. Not only do our employees form the bedrock of our company, but thousands among them are also partners who hold DocGo shares and options. I'm truly thankful to every single DocGo employee for their unrelenting efforts toward making high quality, highly accessible healthcare a reality, and I look forward to collaborating to take DocGo to greater heights in 2023 and beyond; that brings our call this evening to a close. Thanks once more for being with us, and we anticipate our next quarterly update in May.

Operator

operator
#50

That wraps up the call for today. At this point you're free to drop off your lines. We appreciate you taking part.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.